Blood-plasma study of botulism antitoxin in children
Treatments studied
Part of Brain & nervous system, Infections clinical trials.
This trial studies how a botulism antitoxin (called BAT, heptavalent) moves through the body in children. It may help doctors better choose doses and timing for pediatric treatment by learning from blood samples after the first dose.
Summary written for real people, not researchers, by Clin2.
Who can take part
- A parent or legal guardian can agree to the study, and your child can agree if needed.
- The child is between birth and under 12 years old.
- The child is receiving the BAT botulism antitoxin, and only the first dose is used for the study.
- A blood sample (or a standard-care sample) can be taken within 32 hours after the infusion is finished.
- The 5 mL blood sample must be considered safe for the child based on size and health.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called B11-FC to prevent or treat botulism. In the first part, healthy volunteers will receive the drug to check its safety. Later, people with botulism may be included.
This trial tests a one-time injection of botulinum toxin (like Botox) into the bottom muscle to help children who have frequent, stubborn bowel leakage. It aims to see if relaxing the muscle can reduce accidents.
This study tests whether a Botox (botulinum toxin) injection can improve arm and leg movement in children with cerebral palsy. It is for kids ages 8–17 who have stiffness mainly on one side and can walk well.
This study looks at how well a tetanus booster vaccine works by testing your saliva and blood. It includes healthy children, young adults, pregnant women, and adults with certain medical conditions.
This study looks at whether giving common antibiotics in certain dose schedules (either through a drip over time or continuously) is done in a way that fits pediatric intensive care needs. It may help improve antibiotic treatment for children who are very sick and need antibiotics.
This trial tests a new medicine made from antibodies that target tetanus toxin. It may help protect people from tetanus without needing a vaccine.
Hear when a new Botulism trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.